{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:35:13Z","timestamp":1783571713348,"version":"3.55.0"},"reference-count":141,"publisher":"European Respiratory Society (ERS)","issue":"164","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2022,2,21]]},"published-print":{"date-parts":[[2022,6,30]]},"abstract":"<jats:p>Respiratory virus infections initiate in the upper respiratory tract (URT). Innate immunity is critical for initial control of infection at this site, particularly in the absence of mucosal virus-neutralising antibodies. If the innate immune response is inadequate, infection can spread to the lower respiratory tract (LRT) causing community-acquired pneumonia (as exemplified by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\/coronavirus disease 2019). Vaccines for respiratory viruses (influenza and SARS-CoV-2) leverage systemic adaptive immunity to protect from severe lung disease. However, the URT remains vulnerable to infection, enabling viral transmission and posing an ongoing risk of severe disease in populations that lack effective adaptive immunity.<\/jats:p><jats:p>Innate immunity is triggered by host cell recognition of viral pathogen-associated molecular patterns<jats:italic>via<\/jats:italic>molecular sensors such as Toll-like receptors (TLRs). Here we review the role of TLRs in respiratory viral infections and the potential of TLR-targeted treatments to enhance airway antiviral immunity to limit progression to severe LRT disease and reduce person-to-person viral transmission. By considering cellular localisation and antiviral mechanisms of action and treatment route\/timing, we propose that cell surface TLR agonist therapies are a viable strategy for preventing respiratory viral diseases by providing immediate, durable pan-viral protection within the URT.<\/jats:p>","DOI":"10.1183\/16000617.0274-2021","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T08:40:14Z","timestamp":1651653614000},"page":"210274","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell"],"prefix":"10.1183","volume":"31","author":[{"given":"Jason L.N.","family":"Girkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Maltby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2715-5163","authenticated-orcid":false,"given":"Nathan W.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"2024102404033118000_31.164.210274.1","unstructured":"Forum of International Respiratory Societies . The Global Impact of Respiratory Disease. 2nd Edn. Sheffield, European Respiratory Society, 2017."},{"key":"2024102404033118000_31.164.210274.2","unstructured":"Wardlaw TM , Johansson E , Hodge M , et al. World Health Organization & United Nations Children's Fund (UNICEF). Pneumonia: The Forgotten Killer of Children. Geneva, World Health Organization, 2006."},{"key":"2024102404033118000_31.164.210274.3","unstructured":"World Health Organization . WHO reveals leading causes of death and disability worldwide: 2000\u20132019. www.who.int\/news\/item\/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019"},{"key":"2024102404033118000_31.164.210274.4","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/B978-012373944-5.00314-X","article-title":"Respiratory viruses","volume":"2009","author":"Boncristiani","year":"2009","journal-title":"Encyclopedia Microbiology"},{"key":"2024102404033118000_31.164.210274.5","unstructured":"World Health Organization . Influenza (seasonal) factsheet. www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal)"},{"key":"2024102404033118000_31.164.210274.6","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1863"},{"key":"2024102404033118000_31.164.210274.7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002785"},{"key":"2024102404033118000_31.164.210274.8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102404033118000_31.164.210274.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052211"},{"key":"2024102404033118000_31.164.210274.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00731.x"},{"key":"2024102404033118000_31.164.210274.11","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-387664-5.00003-0"},{"key":"2024102404033118000_31.164.210274.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5396.2085"},{"key":"2024102404033118000_31.164.210274.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2012.03.008"},{"key":"2024102404033118000_31.164.210274.14","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.106376"},{"key":"2024102404033118000_31.164.210274.15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117581"},{"key":"2024102404033118000_31.164.210274.16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804181105"},{"key":"2024102404033118000_31.164.210274.17","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41564-019-0421-x","article-title":"Decoding type I and III interferon signalling during viral infection","volume":"4","author":"Mesev","year":"2019","journal-title":"Nat Microbiol"},{"key":"2024102404033118000_31.164.210274.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700250"},{"key":"2024102404033118000_31.164.210274.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.04.025"},{"key":"2024102404033118000_31.164.210274.20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00461"},{"key":"2024102404033118000_31.164.210274.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2003.10.006"},{"key":"2024102404033118000_31.164.210274.22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000503030","article-title":"Innate immune evasion by human respiratory RNA viruses","volume":"12","author":"Kikkert","year":"2020","journal-title":"J Innate Immun"},{"key":"2024102404033118000_31.164.210274.23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041901"},{"key":"2024102404033118000_31.164.210274.24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002114"},{"key":"2024102404033118000_31.164.210274.25","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fimmu.2020.00974","article-title":"Airway epithelial cell immunity is delayed during rhinovirus infection in asthma and COPD","volume":"11","author":"Veerati","year":"2020","journal-title":"Front Immunol"},{"key":"2024102404033118000_31.164.210274.26","doi-asserted-by":"crossref","first-page":"L926","DOI":"10.1152\/ajplung.00374.2020","article-title":"Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in differentiated primary human bronchial epithelial cells","volume":"319","author":"Loo","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2024102404033118000_31.164.210274.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.07.002"},{"key":"2024102404033118000_31.164.210274.28","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040479"},{"key":"2024102404033118000_31.164.210274.29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.25.17406"},{"key":"2024102404033118000_31.164.210274.30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.250476497"},{"key":"2024102404033118000_31.164.210274.31","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0807586"},{"key":"2024102404033118000_31.164.210274.32","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1792"},{"key":"2024102404033118000_31.164.210274.33","doi-asserted-by":"crossref","first-page":"L57","DOI":"10.1152\/ajplung.00365.2018","article-title":"Myristoylated rhinovirus VP4 protein activates TLR2-dependent proinflammatory gene expression","volume":"317","author":"Bentley","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2024102404033118000_31.164.210274.34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41590-021-00937-x","article-title":"TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines","volume":"22","author":"Zheng","year":"2021","journal-title":"Nat Immunol"},{"key":"2024102404033118000_31.164.210274.35","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00985-20"},{"key":"2024102404033118000_31.164.210274.36","doi-asserted-by":"publisher","DOI":"10.1021\/mp300257x"},{"key":"2024102404033118000_31.164.210274.37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00290"},{"key":"2024102404033118000_31.164.210274.38","doi-asserted-by":"crossref","first-page":"e140267","DOI":"10.1172\/jci.insight.140267","article-title":"TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs","volume":"6","author":"Deliyannis","year":"2021","journal-title":"JCI Insight"},{"key":"2024102404033118000_31.164.210274.39","doi-asserted-by":"crossref","first-page":"2001584","DOI":"10.1183\/13993003.01584-2020","article-title":"TLR2-mediated innate immune priming boosts lung anti-viral immunity","volume":"58","author":"Girkin","year":"2021","journal-title":"Eur Respir J"},{"key":"2024102404033118000_31.164.210274.40","doi-asserted-by":"crossref","first-page":"103153","DOI":"10.1016\/j.ebiom.2020.103153","article-title":"Prophylactic intranasal administration of a TLR2\/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model","volume":"63","author":"Proud","year":"2021","journal-title":"EBioMed"},{"key":"2024102404033118000_31.164.210274.41","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032414-112240"},{"key":"2024102404033118000_31.164.210274.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2008.01.006"},{"key":"2024102404033118000_31.164.210274.43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1424980112"},{"key":"2024102404033118000_31.164.210274.44","doi-asserted-by":"publisher","DOI":"10.1038\/ni1569"},{"key":"2024102404033118000_31.164.210274.45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007390"},{"key":"2024102404033118000_31.164.210274.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.09.004"},{"key":"2024102404033118000_31.164.210274.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00572-1"},{"key":"2024102404033118000_31.164.210274.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(02)02426-5"},{"key":"2024102404033118000_31.164.210274.49","doi-asserted-by":"crossref","first-page":"705080","DOI":"10.3389\/fimmu.2021.705080","article-title":"Targeting TLR4 signaling to blunt viral-mediated acute lung injury","volume":"12","author":"Shirey","year":"2021","journal-title":"Front Immunol"},{"key":"2024102404033118000_31.164.210274.50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12985-020-01463-2","article-title":"Toll-like receptor-mediated innate immunity against herpesviridae infection: a current perspective on viral infection signaling pathways","volume":"17","author":"Zheng","year":"2020","journal-title":"Virol J"},{"key":"2024102404033118000_31.164.210274.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.086"},{"key":"2024102404033118000_31.164.210274.52","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1016\/j.vaccine.2014.06.013","article-title":"A rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of influenza B globular head vaccines","volume":"32","author":"Song","year":"2014","journal-title":"Vaccine"},{"key":"2024102404033118000_31.164.210274.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.060"},{"key":"2024102404033118000_31.164.210274.54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2019.05.002","article-title":"Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir","volume":"168","author":"Georgel","year":"2019","journal-title":"Antiviral Res"},{"key":"2024102404033118000_31.164.210274.55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096165"},{"key":"2024102404033118000_31.164.210274.56","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/mi.2013.66","article-title":"Airway structural cells regulate TLR5-mediated mucosal adjuvant activity","volume":"7","author":"Van Maele","year":"2013","journal-title":"Mucosal Immunol"},{"key":"2024102404033118000_31.164.210274.57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000562"},{"key":"2024102404033118000_31.164.210274.58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1410293111"},{"key":"2024102404033118000_31.164.210274.59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601335"},{"key":"2024102404033118000_31.164.210274.60","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3A1116-492R"},{"key":"2024102404033118000_31.164.210274.61","first-page":"859","article-title":"Stable Toll-like receptor 10 knockdown in THP-1 cells reduces TLR-ligand-induced proinflammatory cytokine expression","volume":"17","author":"Le","year":"2016","journal-title":"Int"},{"key":"2024102404033118000_31.164.210274.62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1324266111"},{"key":"2024102404033118000_31.164.210274.63","doi-asserted-by":"publisher","DOI":"10.1038\/nature02761"},{"key":"2024102404033118000_31.164.210274.64","doi-asserted-by":"publisher","DOI":"10.1038\/ni1303"},{"key":"2024102404033118000_31.164.210274.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.048"},{"key":"2024102404033118000_31.164.210274.66","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.6.3368"},{"key":"2024102404033118000_31.164.210274.67","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/mi.2012.86","article-title":"Double-stranded RNA induces molecular and inflammatory signatures that are directly relevant to COPD","volume":"6","author":"Harris","year":"2013","journal-title":"Mucosal Immunol"},{"key":"2024102404033118000_31.164.210274.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2004.07.002"},{"key":"2024102404033118000_31.164.210274.69","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr588"},{"key":"2024102404033118000_31.164.210274.70","doi-asserted-by":"publisher","DOI":"10.1038\/35099560"},{"key":"2024102404033118000_31.164.210274.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2010.07.008"},{"key":"2024102404033118000_31.164.210274.72","first-page":"113","article-title":"PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA","volume":"4","author":"Shen","year":"2007","journal-title":"Cell Mol Immunol"},{"key":"2024102404033118000_31.164.210274.73","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00996-14"},{"key":"2024102404033118000_31.164.210274.74","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.11.2574"},{"key":"2024102404033118000_31.164.210274.75","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00439-3"},{"key":"2024102404033118000_31.164.210274.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.01.051"},{"key":"2024102404033118000_31.164.210274.77","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093616"},{"key":"2024102404033118000_31.164.210274.78","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093620"},{"key":"2024102404033118000_31.164.210274.79","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M504951200"},{"key":"2024102404033118000_31.164.210274.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.02.015"},{"key":"2024102404033118000_31.164.210274.81","doi-asserted-by":"publisher","DOI":"10.1038\/ni1118"},{"key":"2024102404033118000_31.164.210274.82","doi-asserted-by":"publisher","DOI":"10.1038\/nature03547"},{"key":"2024102404033118000_31.164.210274.83","doi-asserted-by":"publisher","DOI":"10.1038\/nature03464"},{"key":"2024102404033118000_31.164.210274.84","doi-asserted-by":"publisher","DOI":"10.1038\/nri1900"},{"key":"2024102404033118000_31.164.210274.85","doi-asserted-by":"publisher","DOI":"10.1038\/nri2358"},{"key":"2024102404033118000_31.164.210274.86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.03.044"},{"key":"2024102404033118000_31.164.210274.87","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200708"},{"key":"2024102404033118000_31.164.210274.88","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202909"},{"key":"2024102404033118000_31.164.210274.89","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205465"},{"key":"2024102404033118000_31.164.210274.90","doi-asserted-by":"crossref","first-page":"599083","DOI":"10.3389\/fimmu.2020.599083","article-title":"Toll-like receptor agonists as adjuvants for allergen immunotherapy","volume":"11","author":"Kirtland","year":"2020","journal-title":"Front Immunol"},{"key":"2024102404033118000_31.164.210274.91","doi-asserted-by":"publisher","DOI":"10.1016\/S0192-0561(98)00068-X"},{"key":"2024102404033118000_31.164.210274.92","first-page":"S11","article-title":"Immune response modification: imiquimod","volume":"39","author":"Tyring","year":"1998","journal-title":"Aust J Dermatol"},{"key":"2024102404033118000_31.164.210274.93","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03337-14"},{"key":"2024102404033118000_31.164.210274.94","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12879-017-2189-z","article-title":"Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line","volume":"17","author":"Das","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2024102404033118000_31.164.210274.95","doi-asserted-by":"crossref","first-page":"7936","DOI":"10.1021\/acs.jmedchem.6b00747","article-title":"Novel pyrimidine toll-like receptor 7 and 8 dual agonists to treat hepatitis B virus","volume":"59","author":"McGowan","year":"2016","journal-title":"J Med Chem"},{"key":"2024102404033118000_31.164.210274.96","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3851\/IMP2845","article-title":"Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C","volume":"20","author":"Lawitz","year":"2015","journal-title":"Antivir Ther"},{"key":"2024102404033118000_31.164.210274.97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.037"},{"key":"2024102404033118000_31.164.210274.98","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.003"},{"key":"2024102404033118000_31.164.210274.99","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.02.092"},{"key":"2024102404033118000_31.164.210274.100","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.60"},{"key":"2024102404033118000_31.164.210274.101","doi-asserted-by":"crossref","first-page":"e20201631","DOI":"10.1084\/jem.20201631","article-title":"A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza","volume":"218","author":"Rappe","year":"2021","journal-title":"J Exp Med"},{"key":"2024102404033118000_31.164.210274.102","doi-asserted-by":"crossref","first-page":"L500","DOI":"10.1152\/ajplung.00237.2019","article-title":"Airway epithelial-targeted nanoparticles for asthma therapy","volume":"318","author":"Kan","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2024102404033118000_31.164.210274.103","doi-asserted-by":"publisher","DOI":"10.1038\/35047123"},{"key":"2024102404033118000_31.164.210274.104","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1189\/jlb.71.3.538","article-title":"Toll-like receptor 9 mediates CpG-DNA signaling","volume":"71","author":"Chuang","year":"2002","journal-title":"J Leukoc Biol"},{"key":"2024102404033118000_31.164.210274.105","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.9.4531"},{"key":"2024102404033118000_31.164.210274.106","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2006.11.007"},{"key":"2024102404033118000_31.164.210274.107","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33940"},{"key":"2024102404033118000_31.164.210274.108","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fcimb.2012.00122","article-title":"Toll-like receptor sensing of human herpesvirus infection","volume":"2","author":"West","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"key":"2024102404033118000_31.164.210274.109","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.964"},{"key":"2024102404033118000_31.164.210274.110","doi-asserted-by":"crossref","first-page":"601685","DOI":"10.3389\/fphar.2020.601685","article-title":"TLR9 and COVID-19: a multidisciplinary theory of a multifaceted therapeutic target","volume":"11","author":"Bezemer","year":"2021","journal-title":"Front Pharmacol"},{"key":"2024102404033118000_31.164.210274.111","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.4161\/hv.27675","article-title":"Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity","volume":"10","author":"Dasari","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"2024102404033118000_31.164.210274.112","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03309-13"},{"key":"2024102404033118000_31.164.210274.113","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200411000-00006"},{"key":"2024102404033118000_31.164.210274.114","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21773"},{"key":"2024102404033118000_31.164.210274.115","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/135965350701200501","article-title":"Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON\u2122), an investigational synthetic Toll-like receptor 9 agonist","volume":"12","author":"Vicari","year":"2007","journal-title":"Antiviral Ther"},{"key":"2024102404033118000_31.164.210274.116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062074"},{"key":"2024102404033118000_31.164.210274.117","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08923973.2013.861481","article-title":"Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis","volume":"36","author":"Qin","year":"2014","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2024102404033118000_31.164.210274.118","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr030"},{"key":"2024102404033118000_31.164.210274.119","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s10637-013-9933-z","article-title":"Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent\/metastatic squamous cell carcinoma of the head and neck","volume":"31","author":"Machiels","year":"2013","journal-title":"Invest New Drugs"},{"key":"2024102404033118000_31.164.210274.120","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00262-014-1547-6","article-title":"Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy","volume":"63","author":"Smith","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2024102404033118000_31.164.210274.121","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.406"},{"key":"2024102404033118000_31.164.210274.122","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell"},{"key":"2024102404033118000_31.164.210274.123","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"key":"2024102404033118000_31.164.210274.124","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y"},{"key":"2024102404033118000_31.164.210274.125","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-015-9090-9"},{"key":"2024102404033118000_31.164.210274.126","doi-asserted-by":"publisher","DOI":"10.2174\/1871527314666150317224645"},{"key":"2024102404033118000_31.164.210274.127","doi-asserted-by":"crossref","unstructured":"Loske J , R\u00f6hmel J , Lukassen S , et al. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat Biotechnol 2022; 40: 316\u2013324.","DOI":"10.1038\/s41587-021-01037-9"},{"key":"2024102404033118000_31.164.210274.128","doi-asserted-by":"crossref","unstructured":"Muus C , Luecken MD , Eraslan G , et al. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. bioRxiv 2022; preprint [https:\/\/doi.org\/10.1101\/2020.04.19.049254]","DOI":"10.1101\/2020.04.19.049254"},{"key":"2024102404033118000_31.164.210274.129","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-021-04345-x","article-title":"Local and systemic responses to SARS-CoV-2 infection in children and adults","volume":"602","author":"Yoshida","year":"2021","journal-title":"Nature"},{"key":"2024102404033118000_31.164.210274.130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2024102404033118000_31.164.210274.131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.10.001"},{"key":"2024102404033118000_31.164.210274.132","doi-asserted-by":"crossref","first-page":"e0180888","DOI":"10.1371\/journal.pone.0180888","article-title":"Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016","volume":"12","author":"Visseaux","year":"2017","journal-title":"PLoS One"},{"key":"2024102404033118000_31.164.210274.133","first-page":"CD006362","article-title":"Non-steroidal anti-inflammatory drugs for the common cold","volume":"8","author":"Kim","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102404033118000_31.164.210274.134","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.42.12.892"},{"key":"2024102404033118000_31.164.210274.135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.14312\/2053-1273.2014-3","article-title":"Developing a vaccine for human rhinoviruses","volume":"2","author":"McLean","year":"2014","journal-title":"J Vaccines Immun"},{"key":"2024102404033118000_31.164.210274.136","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5322.34"},{"key":"2024102404033118000_31.164.210274.137","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5446.1344"},{"key":"2024102404033118000_31.164.210274.138","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-139-36262"},{"key":"2024102404033118000_31.164.210274.139","doi-asserted-by":"crossref","first-page":"12838","DOI":"10.1038\/ncomms12838","article-title":"A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques","volume":"7","author":"Lee","year":"2016","journal-title":"Nat Commun"},{"key":"2024102404033118000_31.164.210274.140","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.07.027"},{"key":"2024102404033118000_31.164.210274.141","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2613"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0274-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:05:04Z","timestamp":1740373504000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0274-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":141,"journal-issue":{"issue":"164","published-online":{"date-parts":[[2022,5,4]]},"published-print":{"date-parts":[[2022,6,30]]}},"alternative-id":["10.1183\/16000617.0274-2021"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0274-2021","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]}}}